# OneMedNet Signs 12th Channel Partner to Expand Pharmaceutical Data Reach

- URL: https://stocks.freetheai.org/news/onemednet-signs-12th-channel-partner-to-expand-pharmaceutical-data-reach-feb9c1
- Published: 2026-10-19T12:45:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:ONMD](https://stocks.freetheai.org/symbols/NASDAQ-ONMD)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

OneMedNet Corporation (NASDAQ:ONMD) announced its 12th channel partnership agreement, partnering with a global provider of pharmaceutical intelligence and data solutions. Under the terms of the deal, the partner will distribute OneMedNet's de-identified clinical data sourced from the United States to pharmaceutical customers across the globe.

The agreement extends OneMedNet's commercial reach while allowing the company to retain direct control over data sourcing, curation, and de-identification. Demand for healthcare data continues to rise as pharmaceutical firms use real-world information for drug development, regulatory filings, and artificial intelligence models. The global real-world data market is estimated at $2.7 billion in 2026 and is projected to grow to $7.1 billion by 2033. OneMedNet's healthcare network currently covers more than 2,300 sites, 90 million patient journeys, and 270 million studies.

Investors will be watching how effectively this partnership converts into increased data delivery and revenue growth. Key metrics to monitor include customer adoption across international pharmaceutical markets, the addition of further distribution channels, and the company's ability to maintain data quality standards while scaling operations.

## Key points

- OneMedNet Corporation signed its 12th channel partner agreement with a global pharmaceutical intelligence provider.
- The partner will distribute OneMedNet's U.S.-sourced, de-identified clinical data to pharmaceutical clients worldwide.
- OneMedNet maintains direct control of its data sourcing and de-identification while leveraging external distribution channels.
- The global real-world data market is estimated at $2.7 billion in 2026 and projected to reach $7.1 billion by 2033.
- OneMedNet's data network includes more than 2,300 sites, 90 million patient journeys, and 270 million studies.

## Questions and answers

### What agreement did OneMedNet sign?

OneMedNet Corporation signed its 12th channel partner agreement, partnering with a global pharmaceutical intelligence provider to distribute its de-identified clinical data to pharmaceutical customers worldwide.

### How large is the real-world data market?

The global real-world data market is estimated at approximately $2.7 billion in 2026 and is projected to reach $7.1 billion by 2033 as pharmaceutical companies increase their use of clinical data.

### What is the scope of OneMedNet's data network?

OneMedNet's network spans more than 2,300 sites and includes over 90 million patient journeys along with 270 million studies.